Can self-navigating ADCs replace chemotherapy in the future?
ADCs are designed to deliver chemotherapy directly to tumours. However, more than 95% of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Self-navigating ADCs, however, might offer a solution.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Fiske, co-founder and chief scientific officer of Mythic Therapeutics, about minimising side effects for patients and the notion of patient-centred science.
In achieving the larger vision of replacing chemotherapy in the future, the issue is improving eligibility for more patients as, in solid tumours, ADCs only really work for patients with high levels of expression.
Fiske discusses the possibilities, including sequencing of therapy, and the excitement of degrader payloads of the future, among much more.
You can listen to episode 150a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!
